Kaspi.kz 1Q26 Results Offer First Concrete Test of Turkey and Dividend Discipline

What happened

Kaspi.kz has released its 1Q 2026 unaudited financial results, providing the first hard data to evaluate whether management's promises of keeping Hepsiburada near breakeven and paying a KZT850/ADS quarterly dividend are translating into reality. The quarter faced notable headwinds in Kazakhstan from a higher bank tax and a step-up in reserve requirements, which are expected to limit net income growth despite solid volume expansion. Investors will now parse the numbers to confirm that the core Payments, Marketplace, and Fintech segments maintained double-digit growth while Turkey showed further operational improvement without additional capital demands. The results also offer an early reading on the impact of the April reserve tightening on loan yields and credit costs. At a P/E of ~6.2x and EV/EBITDA of ~5.1x, the stock's valuation hinges on whether these results support the base case or reveal cracks in the narrative.

Implication

With 1Q26 results now public, investors can directly verify the core thesis that Kaspi can absorb Kazakhstan's regulatory headwinds while funding Turkey's expansion without needing further equity. Focus should be on: (1) Hepsiburada's adjusted EBITDA—any meaningful loss would raise the probability of a second capital injection; (2) Kazakhstan revenue growth and margin resilience despite the 25% bank tax and reserve ratio increases; (3) subsequent quarterly dividend announcements to confirm the payout plan is executable. If the numbers align with management's guidance (TPV +15%, GMV +20%, consolidated EBITDA +5% YoY), the current valuation discount could compress. Failure on any front would strengthen the bear case and push the stock toward our $55 downside scenario. The next 90 days will determine whether the 'show-me' narrative converts to a re-rating or a de-rating.

Thesis delta

The 1Q26 earnings release shifts the thesis from forward-looking expectations to concrete evidence. Previously, we maintained a 'show-me' stance contingent on observable dividend payments and Turkey breakeven. Now, actual performance data will either validate the base case—reinforcing the potential buy rating at current levels—or expose execution problems, which would warrant a downgrade. The central swing factor is whether Hepsiburada's operating discipline holds, as confirmed by this quarter's financial disclosures.